A Phase 2 interventional study of VS-505 and Sevelamer Carbonate in Hyperphosphatemia, sponsored by Shanghai Alebund Pharmaceuticals Limited. Completed at 23 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-10-18.
Sponsored by Shanghai Alebund Pharmaceuticals Limited · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Hyperphosphatemia with a site in China — 6 open to participants now, 6 under way, 1 of them phase 3. Hyperphosphatemia · China.
Among the 18 studies in Hyperphosphatemia with a site in China, this one is the 8th largest by enrollment of the 15 interventional ones that give a count, is one of 3 that started in 2020, is one of 4 in phase 2, and was the 10th registered.
173 studies on the registry are indexed under Hyperphosphatemia; 16 are open to participants now.
Browse Hyperphosphatemia studies →6 of the 18 studies in Hyperphosphatemia with a site in China are open now. Recruiting first, the newest first:
R1 Therapeutics · Sites in China, United States
Ages 18+
Alebund Pharmaceuticals · Sites in China, United States
Ages 12+
Jemincare · Sites in China
Ages 18+
Limeng Chen · Sites in China
Huashan Hospital · Sites in China
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 13 Hyperphosphatemia studies recruiting now, 11 (85%) set no upper age limit and 2 (15%) stop at 75 or younger; 4 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 5 · Phase 3 7 · Phase 4 1
First in 2011; this study’s year is marked. 3 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 158 is above the median of 101 across 143 interventional studies indexed under Hyperphosphatemia.
Median enrollment 158 across the 15 interventional studies, 200 across the 3 observational. Of the 9 that completed or were terminated, 1 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 18 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Shanghai Alebund Pharmaceuticals Limited as lead sponsor.
Shanghai Alebund Pharmaceuticals Limited has 1 study filed under Hyperphosphatemia — fewer than ten, so there is no comparison to draw.
2 of the studies in Hyperphosphatemia with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06712654R1 TherapeuticsA Study to Evaluate Safety, Tolerability and Efficacy of AP306 at Fixed Doses in Dialysis Participants With Hyperphosphatemia | 2027-02-28 |
| NCT07776119Peking University People's HospitalReal-World Efficacy and Safety of Tenapanor Plus Phosphate Binders in Hemodialysis Patients With Hyperphosphatemia | 2027-04-10 |
Add all 2 to your calendar (.ics) → With an account.
Among the 18 studies in Hyperphosphatemia with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A multi-center, open-label, parallel-design, active-controlled phase 2 study to evaluate the tolerability, safety and efficacy of various dosages of VS-505 compared with Sevelamer Carbonate when given orally with meal for 6 weeks to treat hyperphosphatemia in chronic kidney disease subjects receiving maintenance hemodialysis.
The main body of this study has 5 intervention arms, 4 VS-505 treatment arms of various dosage plus 1 active control arm of Sevelamer Carbonate, each consists 25 subjects. Prior to this main part, a dose escalating cohort of 25 subjects is added to evaluate the tolerability of VS-505 in Chinese patient population.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
VS-505 500mg (two 250 mg capsules) oral administration three times a day with meal, daily total dosage 1500mg.
Drug: VS-505
VS-505 750mg (one 750 mg capsule) oral administration three times a day with meal, daily total dosage 2250mg.
Drug: VS-505
VS-505 1500mg (two 750 mg capsules) oral administration three times a day with meal, daily total dosage 4500mg.
Drug: VS-505
VS-505 2250mg (three 750 mg capsules) oral administration three times a day with meal, daily total dosage 6750mg.
Drug: VS-505
Sevelamer Carbonate 1600mg (two 800mg pills) oral administration three times a day with meal, daily total dosage 4800mg.
Drug: Sevelamer Carbonate
4 dosages of experimental drug
Active Comparator
Also known as: Renvela
Serum phosphorus change from baseline to end of treatment
Time frame: 6 weeks
Time to serum phosphorus response,defined as serum phosphorus level decrease by 0.32 mmol/L(1 mg/dL)and serum phosphorus level below 1.78 mmol/L(5.5 mg/dL)
Time frame: 6 weeks
The achievement rate of subjects with serum phosphorus in the target range 1.13-1.78 mmol/L(3.5-5.5 mg/dL)by the end of treatment
Time frame: 6 weeks
Serum calcium change from baseline to end of treatment
Time frame: 6 weeks
Serum Ca×P change from baseline to end of treatment
Time frame: 6 weeks
Serum iPTH change from baseline to end of treatment
Time frame: 6 weeks
Serum ferritin change from baseline to end of treatment
Time frame: 6 weeks
Number of serious adverse events (SAEs)
Time frame: 6 weeks
Ran from Oct 2020 to primary completion in Jun 2022, 20 months.
Of 13 phase 2 interventional studies under Hyperphosphatemia, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 10. This study's 20 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.